1
|
Milhem C, Moralès O, Ingelaere C, Pasquier D, Mordon S, Mortier L, Mirabel X, Delhem N. Combination of High Dose Hypofractionated Radiotherapy with Anti-PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient. Int J Mol Sci 2020; 21:ijms21186772. [PMID: 32942768 PMCID: PMC7555181 DOI: 10.3390/ijms21186772] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Revised: 09/04/2020] [Accepted: 09/08/2020] [Indexed: 12/17/2022] Open
Abstract
The development of immunotherapy has recently modified the anti-tumor therapeutic arsenal; particularly, immune checkpoint inhibitors have led to a significant increase in overall survival. The current challenge is now to select good responder patients by identifying early biomarkers to propose therapeutic combinations that potentiate the efficacy of the therapy. Here we report the case of a 60-year-old man with superficial melanoma treated with high-dose hypo fractionated radiotherapy (H-SRT) combined with a single dose of anti-PD1 immunotherapy (Nivolumab) for a metastatic lymph node recurrence due to cancer progression. In this study, we present the results obtained regarding the activation of the Th1 immune response after H-SRT treatment followed by anti PD-1 therapeutic protocol. These results were correlated with clinical data to identify potential immunological biomarkers of treatment efficacy. This exceptional case report shows that a combination of H-SRT with a single dose of anti-PD1 immunotherapy may allow a better activation of the immune response in favor of a complete clinical response.
Collapse
Affiliation(s)
- Clara Milhem
- INSERM, CHU-Lille, U1189—ONCO-THAI—Assisted Laser Therapy and Immunotherapy for Oncology, University of Lille, F-59000 Lille, France; (C.M.); (O.M.); (S.M.)
- Immune Insight, Institut de Biologie de Lille, 59021 Lille, France;
| | - Olivier Moralès
- INSERM, CHU-Lille, U1189—ONCO-THAI—Assisted Laser Therapy and Immunotherapy for Oncology, University of Lille, F-59000 Lille, France; (C.M.); (O.M.); (S.M.)
- CNRS UMS 3702, Institut de Biologie de Lille, 59021 Lille, France
| | - Céline Ingelaere
- Immune Insight, Institut de Biologie de Lille, 59021 Lille, France;
| | - David Pasquier
- Service de Radiothérapie, Centre Oscar Lambret, 59000 Lille, France;
| | - Serge Mordon
- INSERM, CHU-Lille, U1189—ONCO-THAI—Assisted Laser Therapy and Immunotherapy for Oncology, University of Lille, F-59000 Lille, France; (C.M.); (O.M.); (S.M.)
| | - Laurent Mortier
- Service de Dermatologie, Hôpital Huriez, 59000 Lille, France;
| | - Xavier Mirabel
- Service de Radiothérapie, Centre Oscar Lambret, 59000 Lille, France;
- Correspondence: (X.M.); (N.D.); Tel.: +33-3-20-29-55-26 (X.M.); +33-3-20-87-12-53 (N.D.); Fax: +33-3-20-87-10-19 (N.D.)
| | - Nadira Delhem
- INSERM, CHU-Lille, U1189—ONCO-THAI—Assisted Laser Therapy and Immunotherapy for Oncology, University of Lille, F-59000 Lille, France; (C.M.); (O.M.); (S.M.)
- Correspondence: (X.M.); (N.D.); Tel.: +33-3-20-29-55-26 (X.M.); +33-3-20-87-12-53 (N.D.); Fax: +33-3-20-87-10-19 (N.D.)
| |
Collapse
|
2
|
Apport du guidage par l’image pour le repositionnement au cours de la radiothérapie des tumeurs encéphaliques. Cancer Radiother 2018; 22:593-601. [DOI: 10.1016/j.canrad.2018.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Accepted: 06/29/2018] [Indexed: 11/20/2022]
|